Letter from the Editor: Evidentiary standards may be entering a much-needed new era

All CEOs, all heads of R&D, all drug developers center their strategies around the central question: what is the level of evidence we need to get our therapy approved?

While the question has been around for as long as the industry, the answer is continually changing. ...